Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples

Autor: Johannes A. Hainfellner, Martin Filipits, Sabine Spiegl-Kreinecker, Anna S. Berghoff, Christopher L. Corless, Andrew Kohlway, Michael Bates, Kriszten Kocmond, Edwin W. Lai, Matthias Preusser, Jodi Weidler
Rok vydání: 2020
Předmět:
Zdroj: Anticancer Research. 40:6229-6236
ISSN: 1791-7530
0250-7005
DOI: 10.21873/anticanres.14643
Popis: Background/aim To compare the GeneXpert® O6-methylguanine DNA methyltransferase (MGMT) methylation prototype (GX MGMT) assay with pyrosequencing in glioblastomas. Materials and methods The MGMT methylation status was retrospectively assessed in formalin-fixed paraffin embedded (FFPE) tumor blocks from 262 glioblastoma patients obtained from three independent cohorts using either a standard of care pyrosequencing laboratory developed test or the GX MGMT assay. Results The concordance rate was 92.1% (58/63) for Oregon Health and Science University (OSHU) samples, 91.7% (88/96) for Medical University of Vienna (MUV) samples, and 82.5% (85/103) for Kepler University Hospital (KUH) samples. Patients with MGMT promoter hypermethylation assessed by pyrosequencing or the GX MGMT test had a significantly longer overall survival compared to patients without hypermethylation (HR=0.43, 95%CI=0.26-0.72, p=0.001 and HR=0.51, 95%CI=0.31-0.84, p=0.008, respectively). Conclusion Standardized, simplified, and on-demand testing of MGMT promoter methylation by the GX MGMT assay is feasible.
Databáze: OpenAIRE